MedTech Dive April 22, 2024
Nick Paul Taylor

Lumicell developed the technology to help physicians detect residual cancer in the breast cavity after surgery.

Dive Brief:

  • The Food and Drug Administration approved Lumicell’s breast cancer imaging tool, the company said Thursday.
  • Lumicell developed the Lumisystem imaging technology to enable surgeons to detect residual cancer in the breast cavity after performing a lumpectomy to remove the tumor.
  • An FDA advisory committee voted in March that the benefits of Lumisystem outweigh the risks, with one expert predicting the system will have the biggest impact on surgeons who have higher re-excision rates.

Dive Insight:

Lumisystem has two components called Lumisight and Lumicell DVS. Lumisight is a molecule that reacts to enzymes found at higher levels in and near tumor...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices
Related Articles:
‘He needs to do much more’: RFK Jr.'s measles response under scrutiny
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled

Share This Article